Biologics
Page 1 • 2 itemsGlobal biologics market intelligence: Discover regulatory updates, R&D trends, and investment opportunities in biopharmaceuticals.
Mabwell's MAIWEIJIAN Denosumab Injection Receives NMPA Acceptance for Expanded Cancer Bone Complications Treatment
China's NMPA accepts Mabwell's supplemental biologics license for MAIWEIJIAN denosumab to prevent bone complications in multiple myeloma and solid tumor patients.
GSK's Depemokimab Receives European and Chinese Approvals, Expanding Global Access to Ultra-Long-Acting Biologic
GSK's depemokimab gains regulatory approval from European Commission and China's NMPA, adding to existing approvals in US, Japan, and UK markets.